TP53 and cancer: Inhibiting the interaction between wild-type p53 and MDM2 was one of the main strategies to develop compounds targeting dysfunctional p53 for cancer treatment [45,46], which has been introduced into clinical trials, showing that solid tumor patients with MDM2 amplification as well as wild-type or functional TP53 could benefit from MDM2 inhibitors, milademetan, and ALRN-6924 [17,18,19,47].